nodes	percent_of_prediction	percent_of_DWPC	metapath
Gadoversetamide—Hair disorder—Hydrochlorothiazide—nephrolithiasis	0.0845	0.0845	CcSEcCtD
Gadoversetamide—Creatine phosphokinase increased—Hydrochlorothiazide—nephrolithiasis	0.0365	0.0365	CcSEcCtD
Gadoversetamide—Anorectal disorder—Hydrochlorothiazide—nephrolithiasis	0.0365	0.0365	CcSEcCtD
Gadoversetamide—Blood creatine phosphokinase increased—Hydrochlorothiazide—nephrolithiasis	0.0279	0.0279	CcSEcCtD
Gadoversetamide—Feeling hot—Hydrochlorothiazide—nephrolithiasis	0.0245	0.0245	CcSEcCtD
Gadoversetamide—Numbness—Hydrochlorothiazide—nephrolithiasis	0.0232	0.0232	CcSEcCtD
Gadoversetamide—Sensory loss—Hydrochlorothiazide—nephrolithiasis	0.0222	0.0222	CcSEcCtD
Gadoversetamide—Musculoskeletal stiffness—Hydrochlorothiazide—nephrolithiasis	0.0214	0.0214	CcSEcCtD
Gadoversetamide—Ecchymosis—Hydrochlorothiazide—nephrolithiasis	0.0174	0.0174	CcSEcCtD
Gadoversetamide—Sleep disorder—Hydrochlorothiazide—nephrolithiasis	0.0161	0.0161	CcSEcCtD
Gadoversetamide—Nasal congestion—Hydrochlorothiazide—nephrolithiasis	0.0153	0.0153	CcSEcCtD
Gadoversetamide—Injury—Hydrochlorothiazide—nephrolithiasis	0.0152	0.0152	CcSEcCtD
Gadoversetamide—Increased appetite—Hydrochlorothiazide—nephrolithiasis	0.0148	0.0148	CcSEcCtD
Gadoversetamide—Thirst—Hydrochlorothiazide—nephrolithiasis	0.0146	0.0146	CcSEcCtD
Gadoversetamide—Hyponatraemia—Hydrochlorothiazide—nephrolithiasis	0.014	0.014	CcSEcCtD
Gadoversetamide—Face oedema—Hydrochlorothiazide—nephrolithiasis	0.0135	0.0135	CcSEcCtD
Gadoversetamide—Blood creatinine increased—Hydrochlorothiazide—nephrolithiasis	0.0131	0.0131	CcSEcCtD
Gadoversetamide—Dry skin—Hydrochlorothiazide—nephrolithiasis	0.0128	0.0128	CcSEcCtD
Gadoversetamide—Muscular weakness—Hydrochlorothiazide—nephrolithiasis	0.0123	0.0123	CcSEcCtD
Gadoversetamide—Alanine aminotransferase increased—Hydrochlorothiazide—nephrolithiasis	0.0123	0.0123	CcSEcCtD
Gadoversetamide—Dysphagia—Hydrochlorothiazide—nephrolithiasis	0.012	0.012	CcSEcCtD
Gadoversetamide—Influenza—Hydrochlorothiazide—nephrolithiasis	0.012	0.012	CcSEcCtD
Gadoversetamide—Dysuria—Hydrochlorothiazide—nephrolithiasis	0.0113	0.0113	CcSEcCtD
Gadoversetamide—Hyperglycaemia—Hydrochlorothiazide—nephrolithiasis	0.0109	0.0109	CcSEcCtD
Gadoversetamide—Pneumonia—Hydrochlorothiazide—nephrolithiasis	0.0108	0.0108	CcSEcCtD
Gadoversetamide—Conjunctivitis—Hydrochlorothiazide—nephrolithiasis	0.0104	0.0104	CcSEcCtD
Gadoversetamide—Urinary tract infection—Hydrochlorothiazide—nephrolithiasis	0.0104	0.0104	CcSEcCtD
Gadoversetamide—Haematuria—Hydrochlorothiazide—nephrolithiasis	0.0102	0.0102	CcSEcCtD
Gadoversetamide—Epistaxis—Hydrochlorothiazide—nephrolithiasis	0.0101	0.0101	CcSEcCtD
Gadoversetamide—Sinusitis—Hydrochlorothiazide—nephrolithiasis	0.0101	0.0101	CcSEcCtD
Gadoversetamide—Rhinitis—Hydrochlorothiazide—nephrolithiasis	0.00966	0.00966	CcSEcCtD
Gadoversetamide—Hypoaesthesia—Hydrochlorothiazide—nephrolithiasis	0.00959	0.00959	CcSEcCtD
Gadoversetamide—Pharyngitis—Hydrochlorothiazide—nephrolithiasis	0.00957	0.00957	CcSEcCtD
Gadoversetamide—Oedema peripheral—Hydrochlorothiazide—nephrolithiasis	0.00949	0.00949	CcSEcCtD
Gadoversetamide—Erythema multiforme—Hydrochlorothiazide—nephrolithiasis	0.00911	0.00911	CcSEcCtD
Gadoversetamide—Tinnitus—Hydrochlorothiazide—nephrolithiasis	0.00899	0.00899	CcSEcCtD
Gadoversetamide—Flushing—Hydrochlorothiazide—nephrolithiasis	0.00895	0.00895	CcSEcCtD
Gadoversetamide—Arrhythmia—Hydrochlorothiazide—nephrolithiasis	0.00861	0.00861	CcSEcCtD
Gadoversetamide—Erythema—Hydrochlorothiazide—nephrolithiasis	0.00839	0.00839	CcSEcCtD
Gadoversetamide—Flatulence—Hydrochlorothiazide—nephrolithiasis	0.00827	0.00827	CcSEcCtD
Gadoversetamide—Tension—Hydrochlorothiazide—nephrolithiasis	0.00823	0.00823	CcSEcCtD
Gadoversetamide—Dysgeusia—Hydrochlorothiazide—nephrolithiasis	0.00822	0.00822	CcSEcCtD
Gadoversetamide—Nervousness—Hydrochlorothiazide—nephrolithiasis	0.00815	0.00815	CcSEcCtD
Gadoversetamide—Back pain—Hydrochlorothiazide—nephrolithiasis	0.00812	0.00812	CcSEcCtD
Gadoversetamide—Muscle spasms—Hydrochlorothiazide—nephrolithiasis	0.00807	0.00807	CcSEcCtD
Gadoversetamide—Vision blurred—Hydrochlorothiazide—nephrolithiasis	0.00791	0.00791	CcSEcCtD
Gadoversetamide—Tremor—Hydrochlorothiazide—nephrolithiasis	0.00786	0.00786	CcSEcCtD
Gadoversetamide—Ill-defined disorder—Hydrochlorothiazide—nephrolithiasis	0.00778	0.00778	CcSEcCtD
Gadoversetamide—Agitation—Hydrochlorothiazide—nephrolithiasis	0.00771	0.00771	CcSEcCtD
Gadoversetamide—Malaise—Hydrochlorothiazide—nephrolithiasis	0.00757	0.00757	CcSEcCtD
Gadoversetamide—Vertigo—Hydrochlorothiazide—nephrolithiasis	0.00754	0.00754	CcSEcCtD
Gadoversetamide—Syncope—Hydrochlorothiazide—nephrolithiasis	0.00752	0.00752	CcSEcCtD
Gadoversetamide—Palpitations—Hydrochlorothiazide—nephrolithiasis	0.00741	0.00741	CcSEcCtD
Gadoversetamide—Loss of consciousness—Hydrochlorothiazide—nephrolithiasis	0.00737	0.00737	CcSEcCtD
Gadoversetamide—Cough—Hydrochlorothiazide—nephrolithiasis	0.00732	0.00732	CcSEcCtD
Gadoversetamide—Myalgia—Hydrochlorothiazide—nephrolithiasis	0.00714	0.00714	CcSEcCtD
Gadoversetamide—Arthralgia—Hydrochlorothiazide—nephrolithiasis	0.00714	0.00714	CcSEcCtD
Gadoversetamide—Chest pain—Hydrochlorothiazide—nephrolithiasis	0.00714	0.00714	CcSEcCtD
Gadoversetamide—Anxiety—Hydrochlorothiazide—nephrolithiasis	0.00712	0.00712	CcSEcCtD
Gadoversetamide—Discomfort—Hydrochlorothiazide—nephrolithiasis	0.00706	0.00706	CcSEcCtD
Gadoversetamide—Dry mouth—Hydrochlorothiazide—nephrolithiasis	0.00699	0.00699	CcSEcCtD
Gadoversetamide—Confusional state—Hydrochlorothiazide—nephrolithiasis	0.0069	0.0069	CcSEcCtD
Gadoversetamide—Oedema—Hydrochlorothiazide—nephrolithiasis	0.00685	0.00685	CcSEcCtD
Gadoversetamide—Anaphylactic shock—Hydrochlorothiazide—nephrolithiasis	0.00685	0.00685	CcSEcCtD
Gadoversetamide—Shock—Hydrochlorothiazide—nephrolithiasis	0.00674	0.00674	CcSEcCtD
Gadoversetamide—Thrombocytopenia—Hydrochlorothiazide—nephrolithiasis	0.0067	0.0067	CcSEcCtD
Gadoversetamide—Tachycardia—Hydrochlorothiazide—nephrolithiasis	0.00668	0.00668	CcSEcCtD
Gadoversetamide—Hyperhidrosis—Hydrochlorothiazide—nephrolithiasis	0.00662	0.00662	CcSEcCtD
Gadoversetamide—Anorexia—Hydrochlorothiazide—nephrolithiasis	0.00653	0.00653	CcSEcCtD
Gadoversetamide—Hypotension—Hydrochlorothiazide—nephrolithiasis	0.0064	0.0064	CcSEcCtD
Gadoversetamide—Musculoskeletal discomfort—Hydrochlorothiazide—nephrolithiasis	0.00624	0.00624	CcSEcCtD
Gadoversetamide—Insomnia—Hydrochlorothiazide—nephrolithiasis	0.00619	0.00619	CcSEcCtD
Gadoversetamide—Paraesthesia—Hydrochlorothiazide—nephrolithiasis	0.00615	0.00615	CcSEcCtD
Gadoversetamide—Dyspnoea—Hydrochlorothiazide—nephrolithiasis	0.0061	0.0061	CcSEcCtD
Gadoversetamide—Somnolence—Hydrochlorothiazide—nephrolithiasis	0.00609	0.00609	CcSEcCtD
Gadoversetamide—Dyspepsia—Hydrochlorothiazide—nephrolithiasis	0.00603	0.00603	CcSEcCtD
Gadoversetamide—Decreased appetite—Hydrochlorothiazide—nephrolithiasis	0.00595	0.00595	CcSEcCtD
Gadoversetamide—Fatigue—Hydrochlorothiazide—nephrolithiasis	0.0059	0.0059	CcSEcCtD
Gadoversetamide—Pain—Hydrochlorothiazide—nephrolithiasis	0.00586	0.00586	CcSEcCtD
Gadoversetamide—Constipation—Hydrochlorothiazide—nephrolithiasis	0.00586	0.00586	CcSEcCtD
Gadoversetamide—Feeling abnormal—Hydrochlorothiazide—nephrolithiasis	0.00564	0.00564	CcSEcCtD
Gadoversetamide—Gastrointestinal pain—Hydrochlorothiazide—nephrolithiasis	0.0056	0.0056	CcSEcCtD
Gadoversetamide—Urticaria—Hydrochlorothiazide—nephrolithiasis	0.00544	0.00544	CcSEcCtD
Gadoversetamide—Abdominal pain—Hydrochlorothiazide—nephrolithiasis	0.00541	0.00541	CcSEcCtD
Gadoversetamide—Body temperature increased—Hydrochlorothiazide—nephrolithiasis	0.00541	0.00541	CcSEcCtD
Gadoversetamide—Hypersensitivity—Hydrochlorothiazide—nephrolithiasis	0.00505	0.00505	CcSEcCtD
Gadoversetamide—Asthenia—Hydrochlorothiazide—nephrolithiasis	0.00491	0.00491	CcSEcCtD
Gadoversetamide—Pruritus—Hydrochlorothiazide—nephrolithiasis	0.00484	0.00484	CcSEcCtD
Gadoversetamide—Diarrhoea—Hydrochlorothiazide—nephrolithiasis	0.00469	0.00469	CcSEcCtD
Gadoversetamide—Dizziness—Hydrochlorothiazide—nephrolithiasis	0.00453	0.00453	CcSEcCtD
Gadoversetamide—Vomiting—Hydrochlorothiazide—nephrolithiasis	0.00435	0.00435	CcSEcCtD
Gadoversetamide—Rash—Hydrochlorothiazide—nephrolithiasis	0.00432	0.00432	CcSEcCtD
Gadoversetamide—Dermatitis—Hydrochlorothiazide—nephrolithiasis	0.00431	0.00431	CcSEcCtD
Gadoversetamide—Headache—Hydrochlorothiazide—nephrolithiasis	0.00429	0.00429	CcSEcCtD
Gadoversetamide—Nausea—Hydrochlorothiazide—nephrolithiasis	0.00407	0.00407	CcSEcCtD
